Bayer says its Xarelto shows lower risk of stroke, brain haemorrhage for irregular heart rhythm condition vs BMS’ Coumadin
April 19, 2016Manufacturing and Production, Research and Development Bayer, Bristol-Myers Squibb, anti blood-clot, drug trial
New trials for anti blood-clotting drug Xarelto (rivaroxaban) showed lower risk of stroke and haemorrhage in patients with irregular heart …
Bristol-Myers Squibb’s Opdivo shows positive results in early stage trials for advanced skin cancer
April 19, 2016Manufacturing and Production, Research and Development Bristol-Myers Squibb, drug trial, immuno-therapy, oncology, opdivo
New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …
Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials
April 19, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous
Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …
Roche reports 5% rise in Q1 sales boosted by cancer drugs
April 19, 2016Manufacturing and Production, Sales and Marketing Q1, Roche, earnings, oncology drugs, results
Oncology drug maker Roche (VTX: ROG) on Tuesday reported 5% increase in first-quarter sales driven by cancer drugs. The company …
GlaxoSmithKline opens new £56 million facility in Hertfordshire
April 19, 2016Manufacturing and Production Andrew Witty, GSK, GlaxoSmithKline, Sir Andrew Witty, ellipta, facility, george freeman, inhalers, manufacturing, new, respiratory, ware
GlaxoSmithKline has opened a new £56 million manufacturing facility in Hertfordshire, South-East England. The facility in Ware will create 150 …
Eli Lilly drops development of diabetes drug in Phase III
April 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial
US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
MSD receives fourth Breakthrough Therapy Designation for Keytruda
April 19, 2016Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …
Sanofi invests €300 million in new Belgian biologics site
April 19, 2016Manufacturing and Production Belgium, Sanofi, belgian, flanders, geel, investment, manufacturing, pipeline
Sanofi has announced plans to expand its site in Geel, Belgium, with a €300 million investment to support its pipeline …
FDA rejects Chiasma’s new drug application for therapy to treat rare growth disorder
April 18, 2016Research and Development, Sales and Marketing Chiasma Inc, US FDA, drug trial, rare disease
Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …
Novo unveils new research grant to mark World Haemophilia Day
April 18, 2016Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day
Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …
British Biosimilars Association launches in UK
April 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Napp, bba, bgma, british biosimilars association
A new industry body, the British Biosimilars Association, has been formally launched today with the sole focus of increasing the …
Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…
April 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market
Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …
Sticking the boot in
April 18, 2016Sales and Marketing Boots, Cost, Guardian, NHS, prescribing, scandal, unfair
A recent exposé has shone a light on the practices allegedly enforced at the nation’s largest pharmacy. So what exactly …
Sosei‘s Heptares And Kymab to collaborate on developing new antibody therapeutics
April 18, 2016Research and Development, Sales and Marketing Heptares Therapeutics, Kymab Ltd, Sosei Group, collaboration, drug development, immuno-oncology
Japan’s Sosei Group Corp (TSE: 4565) has signed a collaboration deal with Kymab Ltd to develop and market novel antibody …
Roche sues Intas Pharma over patent dispute in India
April 18, 2016Medical Communications, Sales and Marketing India, Roche, anaemia, chronic kidney, intas, intas pharmaceuticals, patent
Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, …
NICE recommends PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy
April 18, 2016Sales and Marketing DMD, Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, regulation
Shares in drug maker PTC Therapeutics (Nasdaq: PTCT) jumped after the National Institute for Health and Care Excellence (NICE) backed …
Shire announces new $400 million biologics plant and 400 new jobs in Ireland
April 18, 2016Manufacturing and Production, Sales and Marketing IDA, Ireland, Shire, investment, meath, shire pharmaceuticals
Shire Pharmaceuticals has announced the expansion of its Irish operations with a new $400 million biologics plant set to deliver …
AstraZeneca hold internal talks for Medivation takeover – reports
April 18, 2016Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover
AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …
Clinical trial initiated to help Paris attacks victims with PTSD
April 15, 2016Medical Communications, Research and Development France, clinical trial, mcgill, mcgill university, terror attacks
Victims of the recent Paris terror attacks have been offered the opportunity to take part in a clinical trial, organised …
Gilead Sciences says Phase III trials for chronic HBV drug meet primary endpoints
April 15, 2016Gilead Sciences, US FDA, chronic hepatitis B, drug trial
Biotech firm Gilead Sciences (NYSE: GILD) on Friday announced positive results from late-stage trials for its drug to treat chronic …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
